KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Net: 2011-2024

Historic Receivables - Net for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $142.1 million.

  • Supernus Pharmaceuticals' Receivables - Net rose 17.77% to $171.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.3 million, marking a year-over-year increase of 17.77%. This contributed to the annual value of $142.1 million for FY2024, which is 1.44% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Receivables - Net of $142.1 million as of FY2024, which was down 1.44% from $144.2 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Receivables - Net peaked at $165.5 million during FY2022, and registered a low of $140.9 million during FY2020.
  • For the 3-year period, Supernus Pharmaceuticals' Receivables - Net averaged around $150.6 million, with its median value being $144.2 million (2023).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Receivables - Net surged by 61.31% in 2020 and then dropped by 12.90% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Receivables - Net stood at $140.9 million in 2020, then climbed by 5.72% to $148.9 million in 2021, then increased by 11.12% to $165.5 million in 2022, then decreased by 12.90% to $144.2 million in 2023, then decreased by 1.44% to $142.1 million in 2024.